Boston Scientific Corporation (NYSE:BSX) – Oppenheimer Holdings boosted their FY2017 earnings per share (EPS) estimates for Boston Scientific Corporation in a research report issued to clients and investors on Friday. Oppenheimer Holdings analyst S. Lichtman now expects that the medical equipment provider will post earnings per share of $1.25 for the year, up from their previous forecast of $1.24. Oppenheimer Holdings has a “Hold” rating and a $29.00 price target on the stock. Oppenheimer Holdings also issued estimates for Boston Scientific Corporation’s FY2018 earnings at $1.38 EPS.
A number of other equities research analysts also recently commented on the company. Zacks Investment Research downgraded Boston Scientific Corporation from a “hold” rating to a “sell” rating in a research report on Wednesday, April 5th. Needham & Company LLC lifted their target price on Boston Scientific Corporation from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, June 22nd. Goldman Sachs Group, Inc. (The) started coverage on Boston Scientific Corporation in a research report on Tuesday, May 16th. They issued a “neutral” rating and a $28.00 target price on the stock. Guggenheim restated a “buy” rating on shares of Boston Scientific Corporation in a research report on Wednesday, April 12th. Finally, Evercore ISI lifted their target price on Boston Scientific Corporation from $26.50 to $28.50 and gave the company an “outperform” rating in a research report on Friday, April 28th. One analyst has rated the stock with a sell rating, five have given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $30.00.
ILLEGAL ACTIVITY NOTICE: “Oppenheimer Holdings Comments on Boston Scientific Corporation’s FY2017 Earnings (BSX)” was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://www.com-unik.info/2017/08/19/oppenheimer-holdings-comments-on-boston-scientific-corporations-fy2017-earnings-bsx-updated-updated.html.
Boston Scientific Corporation (NYSE:BSX) traded down 0.19% during trading on Monday, hitting $26.57. The stock had a trading volume of 1,264,251 shares. The firm has a 50 day moving average of $27.68 and a 200-day moving average of $25.91. Boston Scientific Corporation has a one year low of $19.67 and a one year high of $28.51. The company has a market cap of $36.41 billion, a P/E ratio of 47.53 and a beta of 1.10.
Boston Scientific Corporation (NYSE:BSX) last announced its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.32 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.31 by $0.01. The company had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.21 billion. Boston Scientific Corporation had a return on equity of 23.62% and a net margin of 9.04%. Boston Scientific Corporation’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.27 EPS.
Several hedge funds have recently bought and sold shares of BSX. BlackRock Inc. raised its stake in Boston Scientific Corporation by 2,181.6% in the first quarter. BlackRock Inc. now owns 95,744,545 shares of the medical equipment provider’s stock valued at $2,381,169,000 after buying an additional 91,548,235 shares during the last quarter. FMR LLC raised its stake in Boston Scientific Corporation by 7.6% in the first quarter. FMR LLC now owns 184,708,390 shares of the medical equipment provider’s stock valued at $4,593,698,000 after buying an additional 13,105,596 shares during the last quarter. MARSHALL WACE ASIA Ltd purchased a new stake in Boston Scientific Corporation during the first quarter valued at about $149,859,000. Marshall Wace North America L.P. purchased a new stake in Boston Scientific Corporation during the first quarter valued at about $149,859,000. Finally, Vanguard Group Inc. raised its stake in Boston Scientific Corporation by 4.0% in the first quarter. Vanguard Group Inc. now owns 91,134,744 shares of the medical equipment provider’s stock valued at $2,266,521,000 after buying an additional 3,503,965 shares during the last quarter. 91.96% of the stock is owned by institutional investors and hedge funds.
In other news, CFO Daniel J. Brennan sold 92,158 shares of the company’s stock in a transaction dated Tuesday, July 11th. The stock was sold at an average price of $27.48, for a total transaction of $2,532,501.84. Following the completion of the transaction, the chief financial officer now directly owns 235,421 shares of the company’s stock, valued at approximately $6,469,369.08. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP David A. Pierce sold 2,972 shares of the company’s stock in a transaction dated Friday, June 2nd. The stock was sold at an average price of $27.70, for a total value of $82,324.40. Following the transaction, the senior vice president now directly owns 28,572 shares of the company’s stock, valued at $791,444.40. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 188,556 shares of company stock valued at $5,155,752. Insiders own 0.74% of the company’s stock.
About Boston Scientific Corporation
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
What are top analysts saying about Boston Scientific Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Boston Scientific Corporation and related companies.